Japanese generics firm Sawai Pharmaceutical has continued to benefit from the domestic supply stoppages that set back some of its rivals in its financial second quarter ended 30 September 2021, but its US performance has been hampered by increased competitor launches.
Year-on-year, net sales in H1 increased by 7.9% across the board to ¥97.3bn ($846m), while both domestic sales and core...






